OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 10/28/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.01VolumeN/AAverage Volume4,909 shsMarket Capitalization$13.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acura Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing technologies designed to reduce the potential for prescription drug abuse and misuse. Its proprietary platforms included AVERSION, intended to make certain opioid formulations more difficult to abuse, and IMPEDE, designed to limit the extraction of pseudoephedrine for illicit methamphetamine production. The company’s best-known products included Oxecta, an immediate-release oxycodone formulation using the AVERSION technology, and Nexafed, a pseudoephedrine product incorporating the IMPEDE technology. Acura also pursued licensing, development, and commercialization arrangements with pharmaceutical companies to support the distribution of products based on its technologies. Acura’s activities were primarily focused on the U.S. pharmaceutical market. The company later experienced significant financial and operational difficulties, and its business has largely been associated with its historical products and intellectual property rather than an active, broad commercial product portfolio. Information about its current operations and leadership is limited.AI Generated. May Contain Errors. Read More Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACUR Stock News HeadlinesAcura Pharmaceuticals Secures New Loans Amid Bankruptcy RiskOctober 6, 2026 | tipranks.comAcura Pharmaceuticals Discloses Major SEC Filing DelaysAugust 26, 2026 | tipranks.comMissed SpaceX’s 1,000% winner? Then this is for you…In 2024, SpaceX began ordering from a tiny supplier called Filtronic. Its stock has since climbed more than 1,000 percent. Now Elon Musk is reportedly moving forward on a 119 billion dollar plan, and one overlooked American company has become critical to it. Larry Benedict, a former 900 million dollar hedge fund manager, breaks down the ticker and how investors are getting involved. | Brownstone Research (Ad)Acura Pharmaceuticals Secures Loan Amid Going-Concern RisksAugust 20, 2026 | tipranks.comAcura Pharmaceuticals Secures New Loan Amid Liquidity StrainJuly 24, 2026 | tipranks.comAcura Pharmaceuticals Extends Maturity of Key Secured NoteJuly 1, 2026 | theglobeandmail.comAcura Pharmaceuticals Flags Ongoing SEC Filing DelaysMay 13, 2026 | tipranks.comAcura Pharmaceuticals Secures Insider Loans Amid Liquidity StrainMay 7, 2026 | tipranks.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0005 on January 1st, 2026. Since then, ACUR stock has decreased by 60.0% and is now trading at $0.0002. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) issued its quarterly earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company earned $1.32 million during the quarter. Does Acura Pharmaceuticals have any subsidiaries? Acura Pharmaceuticals subsidiaries include these companies: Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Cardiff Oncology (TROV), Eldorado Gold (EGO), American Eagle Outfitters (AEO), BlackBerry (BB), Advanced Micro Devices (AMD), Anika Therapeutics (ANIK) and Broadcom (AVGO). Company Calendar Last Earnings2/28/2020Today10/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees10Year Founded1935Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,650,000Free Float53,186,000Market Cap$13.33 thousand OptionableNot Optionable Beta-13.15 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:ACUR) was last updated on 10/28/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMissed SpaceX’s 1,000% winner? Then this is for you…In 2024, SpaceX began ordering from a tiny supplier called Filtronic. Its stock has since climbed more than 1,...Brownstone Research | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredTrump’s $16 Trillion Chess Move (signed and highlighted)A newly signed executive order could point to one of the largest resource deals in history, according to Matt ...Monument Traders Alliance | SponsoredDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as ...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
